Cytek Q2 revenue misses expectations, cuts FY outlook
Overview
Cytek Q2 2025 revenue falls 2%, missing analyst expectations, per LSEG data
Net loss narrows to $5.6 mln from $10.4 mln in Q2 2024
Co launches Cytek Aurora Evo system and repurchases $4.5 mln stock in the qtr
Outlook
Cytek narrows 2025 revenue guidance to $196 mln-$205 mln
Company expects full-year revenue growth of -2% to +2%
Result Drivers
REVENUE DECLINE - Lower product revenue in EMEA and APAC contributed to a 2% decline in total revenue
RECURRING REVENUE GROWTH - Service and reagent revenues grew 16%, accounting for 32% of last 12 months' total revenue
INSTRUMENT EXPANSION - Installed base grew by 146 units, representing 3% unit growth, despite challenging macro environment
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Miss | $45.60 mln | $46.30 mln (4 Analysts) |
Q2 Net Income | -$5.58 mln | ||
Q2 Adjusted EBITDA | $1.27 mln | ||
Q2 Adjusted Gross Margin | 52.0% | ||
Q2 Pretax Profit | -$6.78 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Cytek Biosciences Inc is $5.50, about 29.5% above its August 5 closing price of $3.88
Press Release:
